Department of Life Science Informatics Bonn-Aachen International Center for Information Technology, Rheinische Friedrich-Wilhelms-Universität Bonn, Endenicher Allee 19c, D-53115, Bonn, Germany.
Mol Inform. 2018 Sep;37(9-10):e1800024. doi: 10.1002/minf.201800024. Epub 2018 Mar 30.
Kinases are among the most heavily investigated drug targets and inhibition of kinases and kinase-dependent signaling has become a paradigm for therapeutic intervention. Kinase inhibitors and associated activity data have increasing 'big data' character, which presents challenges for computational analysis, but also unprecedented opportunities for learning from compound data and for data-driven medicinal chemistry. Herein, publicly available kinase inhibitor data are evaluated and a number of characteristics are discussed. In addition, selectivity of clinical kinase inhibitors is explored computationally on the basis of recently reported cell-based profiling data. For inhibitors shared by pairs of kinases, selectivity profiles were generated and a variety of selective inhibitors were identified. Uni-directional selectivity profiles revealed inhibitors that were selective for one kinase over the other, while bi-directional profiles uncovered compounds with inverted selectivity for paired kinases.
激酶是研究最多的药物靶点之一,抑制激酶和激酶依赖的信号转导已成为治疗干预的范例。激酶抑制剂和相关的活性数据具有越来越大的“大数据”特征,这给计算分析带来了挑战,但也为从化合物数据中学习和数据驱动的药物化学提供了前所未有的机会。本文对公开的激酶抑制剂数据进行了评估,并讨论了一些特征。此外,还基于最近报道的基于细胞的分析数据,对临床激酶抑制剂的选择性进行了计算探索。对于一对激酶共有的抑制剂,生成了选择性图谱,并确定了多种选择性抑制剂。单向选择性图谱揭示了对一种激酶具有选择性的抑制剂,而双向选择性图谱则发现了对配对激酶具有反转选择性的化合物。